Leustatin

Cladribine, the active ingredient in Leustatin, is an antimetabolite presented as an injectable solution for intravenous use. It selectively depletes lymphocytes by incorporating into DNA, and is indicated for the treatment of hairy cell leukemia in adult patients.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide. The product is manufactured in the European Union and meets EU pharmacovigilance requirements.

Leustatin (cladribine) is used in the management of hematologic malignancies that involve abnormal B‑cell proliferation.

Hairy cell leukemia: induces remission by depleting malignant B‑cells.

Cladribine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during treatment. - Fever: transient elevations in body temperature. - Infections: increased susceptibility to bacterial or viral infections. - Lymphopenia: reduced lymphocyte counts. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe infections: opportunistic or life‑threatening infections. - Autoimmune hemolytic anemia: destruction of red blood cells. - Secondary malignancies: rare development of new cancers. - Severe neutropenia: markedly low neutrophil counts. - Hepatic toxicity: abnormal liver function tests. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.

Cladribine requires careful monitoring and specific safety measures before and during therapy.

Monitor blood counts: perform regular complete blood count assessments. Assess infection risk: screen for active infections prior to initiation. Evaluate organ function: check hepatic and renal function before dosing. Avoid concurrent immunosuppressants: limit use of other myelosuppressive agents. Contraception advised: use effective birth control during treatment and for a defined period after. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - Other cytotoxic chemotherapy: increased myelosuppression risk. - Strong immunosuppressants: heightened infection susceptibility.

Moderate Interactions (Monitor Closely): - Azole antifungals: may affect drug metabolism. - Anticoagulants: monitor for bleeding tendencies. - Antihypertensives: observe blood pressure changes.